Patient partnership in cardiovascular clinical trials.

Clinical trials Drug development Heart disease Patient partner Patient-centred care Patient-oriented research Patient-reported outcomes

Journal

European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263

Informations de publication

Date de publication:
06 04 2022
Historique:
received: 06 08 2021
revised: 18 10 2021
accepted: 22 11 2021
pubmed: 14 12 2021
medline: 9 4 2022
entrez: 13 12 2021
Statut: ppublish

Résumé

Patients are ultimately the end-users of medical therapies and need to be actively integrated as contributors and decision-makers in the process of product development throughout product lifecycles. This is increasingly being recognized by patients, investigators, regulators, payers, sponsors, and medical journals. However, cardiovascular research remains behind other fields in terms of the extent of patient involvement and awareness of clinical trials in cardiovascular research. True patient partnerships in cardiovascular therapeutic development may permit more rapid recognition of unmet needs, ensure alignment of product development priorities with patient priorities, improve efficiency of trials (e.g. recruitment), and ensure outcomes of value to patients are being measured in trials (e.g. quality of life). This paper reviews ongoing initiatives and remaining opportunities to accomplish contributive patient involvement in cardiovascular clinical research.

Identifiants

pubmed: 34897413
pii: 6460258
doi: 10.1093/eurheartj/ehab835
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1432-1437

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Auteurs

Faiez Zannad (F)

Université de Lorraine, Inserm Clinical Investigation Center, Institut Lorrain du Coeur et des Vaisseaux, University Hospital of Nancy, Nancy 54500, France.

Cynthia Chauhan (C)

Wichita, KS, USA.

Patrick O Gee (PO)

North Chesterfield, VA, USA.

Nick Hartshorne-Evans (N)

Pumping Marvellous Foundation, UK.

Adrian F Hernandez (AF)

Duke Clinical Research Institute and Department of Medicine, Duke University School of Medicine, Durham, NC, USA.

Robin Martinez (R)

Smart Patients Inc, USA.

Roxana Mehran (R)

The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH